Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 9/20 | 0.38 |
| ▸ | RBP4 | P02753 | 3/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 6/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1337180 | 0.91 | AOC3 (0.35) | CACNA1BAOC3 | |
| SCHEMBL1337338 | 0.86 | HSD11B1 (0.39) | CACNA1B | |
| SCHEMBL1337326 | 0.85 | KDM4E (0.38) | NOTUMCACNA1B | |
| SCHEMBL1337287 | 0.82 | NOTUM (0.42) | NOTUMCACNA1B | |
| SCHEMBL1337119 | 0.82 | CACNA1B (0.35) | CACNA1B | |
| SCHEMBL1335234 | 0.82 | NOTUM (0.37) | NOTUMCACNA1B | |
| SCHEMBL16498038 | 0.81 | CACNA1B (0.37) | CACNA1B | |
| SCHEMBL16497723 | 0.81 | CACNA1B (0.55) | NOTUMCACNA1B | |
| SCHEMBL1337573 | 0.80 | GRM1 (0.40) | CACNA1B | |
| SCHEMBL1336446 | 0.80 | DRD3 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | claimed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | NOTUM 3350/4885CACNA1B 5/4885RBP4 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.